200 related articles for article (PubMed ID: 32054413)
1. 5-azacitidine reversing "spent" phase polycythemia vera back to proliferative phase and need for phlebotomy.
Lerner J; Michel M; Dasanu CA
J Oncol Pharm Pract; 2020 Jul; 26(5):1285-1288. PubMed ID: 32054413
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
[TBL] [Abstract][Full Text] [Related]
3. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
4. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
5. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
[TBL] [Abstract][Full Text] [Related]
6. Treatment of the myeloproliferative disorders with 32P.
Berlin NI
Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
[TBL] [Abstract][Full Text] [Related]
7. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.
Handa S; Ginzburg Y; Hoffman R; Kremyanskaya M
Curr Opin Hematol; 2023 Mar; 30(2):45-52. PubMed ID: 36728649
[TBL] [Abstract][Full Text] [Related]
9. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis.
Parra Salinas I; Recasens Flores V; Montañés MÁ; García-Erce JA
Med Clin (Barc); 2020 Jan; 154(1):16-19. PubMed ID: 30795904
[TBL] [Abstract][Full Text] [Related]
12. The impact of statins on the intensity of phlebotomies in polycythemia vera.
Krečak I; Holik H; Morić-Perić M; Zekanović I; Coha B; Gverić-Krečak V
Ann Hematol; 2020 Apr; 99(4):911-912. PubMed ID: 32025841
[No Abstract] [Full Text] [Related]
13. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.
Barbui T; Carobbio A; Ghirardi A; Masciulli A; Rambaldi A; Vannucchi AM
Haematologica; 2017 Jun; 102(6):e219-e221. PubMed ID: 28255021
[No Abstract] [Full Text] [Related]
14. Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Habberstad AH; Tran HTT; Randen U; Spetalen S; Dybedal I; Tjønnfjord GE; Dahm AEA
J Med Case Rep; 2018 Apr; 12(1):105. PubMed ID: 29685167
[TBL] [Abstract][Full Text] [Related]
15. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.
Barbui T; Passamonti F; Accorsi P; Pane F; Vannucchi AM; Velati C; Gale RP; Tura S; Barosi G
Leukemia; 2018 Sep; 32(9):2077-2081. PubMed ID: 29955128
[No Abstract] [Full Text] [Related]
16. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
Scherber RM; Geyer HL; Dueck AC; Kosiorek HE; Finazzi G; Cavazzina R; Masciulli A; Scarano M; Vannucchi AM; Mesa RA; Barbui T
Leuk Lymphoma; 2017 Jun; 58(6):1481-1487. PubMed ID: 27830999
[TBL] [Abstract][Full Text] [Related]
17. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients.
Siegel FP; Tauscher J; Petrides PE
Am J Hematol; 2013 Aug; 88(8):665-9. PubMed ID: 23657863
[TBL] [Abstract][Full Text] [Related]
18. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M; Kuykendall AT; Pemmaraju N; Ritchie EK; Gotlib J; Gerds A; Palmer J; Pettit K; Nath UK; Yacoub A; Molina A; Saks SR; Modi NB; Valone FH; Khanna S; Gupta S; Verstovsek S; Ginzburg YZ; Hoffman R;
N Engl J Med; 2024 Feb; 390(8):723-735. PubMed ID: 38381675
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]